Search Results - "Pettitt, Andrew"

Is it time for PET-guided therapy in follicular lymphoma? by Trotman, Judith, Pettitt, Andrew R.

“…18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) is now established as the gold-standard imaging modality for both staging and…”
Get full text

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma by Flinn, Ian W, Miller, Carole B, Ardeshna, Kirit M, Tetreault, Scott, Assouline, Sarit E, Mayer, Jiri, Merli, Michele, Lunin, Scott D, Pettitt, Andrew R, Nagy, Zoltan, Tournilhac, Olivier, Abou-Nassar, Karem-Etienne, Crump, Michael, Jacobsen, Eric D, de Vos, Sven, Kelly, Virginia M, Shi, Weiliang, Steelman, Lori, Le, NgocDiep, Weaver, David T, Lustgarten, Stephanie, Wagner-Johnston, Nina D, Zinzani, Pier Luigi

“…Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies…”
Get full text

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial by Hillmen, Peter, Prof, Robak, Tadeusz, MD, Janssens, Ann, MD, Babu, K Govind, MD, Kloczko, Janusz, MD, Grosicki, Sebastian, MD, Doubek, Michael, MD, Panagiotidis, Panagiotis, MD, Kimby, Eva, MD, Schuh, Anna, MD, Pettitt, Andrew R, MRCPath, Boyd, Thomas, MD, Montillo, Marco, MD, Gupta, Ira V, MD, Wright, Oliver, BSc, Dixon, Iestyn, BSc, Carey, Jodi L, RN BSN, Chang, Chai-Ni, MS, Lisby, Steen, MD, McKeown, Astrid, PhD, Offner, Fritz, MD

“…Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based…”
Get full text

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study by Hillmen, Peter, Rawstron, Andy C, Brock, Kristian, Muñoz-Vicente, Samuel, Yates, Francesca J, Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison, Schuh, Anna, Pettitt, Andrew, Gribben, John G, Patten, Piers E M, Devereux, Stephen, Bloor, Adrian, Fox, Christopher P, Forconi, Francesco, Munir, Talha

“…The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate…”
Get full text

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia by Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, O'Brien, Susan M

“…A placebo-controlled study of idelalisib in patients with relapsed chronic lymphocytic leukemia who were receiving rituximab was stopped early because of…”
Get full text

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia by Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M, Stilgenbauer, Stephan

“…A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic…”
Get full text

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib by Till, Kathleen J., Abdullah, Mariah, Alnassfan, Tahera, Janet, Gallardo Zapata, Marks, Thomas, Coma, Silvia, Weaver, David T., Pachter, Jonathan A., Pettitt, Andrew R., Slupsky, Joseph R.

“…Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma that is incurable with existing therapies, and therefore presents a significant unmet…”
Get full text

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial by PETTITT, Andrew R, JACKSON, Richard, CATOVSKY, Daniel, RADFORD, John A, BLOOR, Adrian, FOLLOWS, George A, DEVEREUX, Stephen, KRUGER, Anton, BLUNDELL, Julie, AGRAWAL, Samir, ALLSUP, David, PROCTOR, Stephen, CARRUTHERS, Stacey, HEARTIN, Earnest, OSCIER, David, HAMBLIN, Terry J, RAWSTRON, Andrew, HILLMEN, Peter, DODD, James, DODD, Susanna, OATES, Melanie, JOHNSON, Gillian G, SCHUH, Anna, MATUTES, Estella, DEARDEN, Claire E

“…In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In…”
Get full text

Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells by Till, Kathleen J, Pettitt, Andrew R, Slupsky, Joseph R

“…BCR signaling pathway inhibitors such as ibrutinib, idelalisib, and fostamatinib (respective inhibitors of Bruton's tyrosine kinase, PI3Kδ, and spleen tyrosine…”
Get full text

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study by HILLMEN, Peter, GRIBBEN, John G, NATHWANI, Amit, VARGHESE, Abraham, COHEN, Dena, RAWSTRON, Andy, OERTEL, Stephan, POCOCK, Christopher F. E, FOLLOWS, George A, MILLIGAN, Donald, SAYALA, Hazem A, MORETON, Paul, OSCIER, David G, DEARDEN, Claire E, KENNEDY, Daniel B, PETTITT, Andrew R

“…Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For…”
Get full text

Patient and health practitioner views and experiences of a cancer trial before and during COVID-19: qualitative study by Sherratt, Frances C, Fisher, Peter, Mathieson, Amy, Cherry, Mary G, Pettitt, Andrew R, Young, Bridget

“…Abstract Background Understanding patient and health practitioner perspectives on clinical trials can inform opportunities to enhance trial conduct and design,…”
Get full text

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage by Clifford, Ruth, Louis, Tania, Robbe, Pauline, Ackroyd, Sam, Burns, Adam, Timbs, Adele T., Wright Colopy, Glen, Dreau, Helene, Sigaux, Francois, Judde, Jean Gabriel, Rotger, Margalida, Telenti, Amalio, Lin, Yea-Lih, Pasero, Philippe, Maelfait, Jonathan, Titsias, Michalis, Cohen, Dena R., Henderson, Shirley J., Ross, Mark T., Bentley, David, Hillmen, Peter, Pettitt, Andrew, Rehwinkel, Jan, Knight, Samantha J.L., Taylor, Jenny C., Crow, Yanick J., Benkirane, Monsef, Schuh, Anna

“…SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase and a nuclease that restricts HIV-1 in noncycling cells. Germ-line mutations in SAMHD1 have been…”
Get full text

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab by Kreuzer, Karl-Anton, Furman, Richard R., Stilgenbauer, Stephan, Dubowy, Ronald L., Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara, Hillmen, Peter, O’Brien, Susan M., Pettitt, Andrew R., Hallek, Michael

Get full text

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial by Ghia, Paolo, Coutre, Steven E, Cheson, Bruce D, Barrientos, Jacqueline C, Hillmen, Peter, Pettitt, Andrew R, Zelenetz, Andrew D, Shreay, Sanatan, Hallek, Michael, Furman, Richard R

Get full text

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Eyre, Toby A., Clifford, Ruth, Bloor, Adrian, Boyle, Lucy, Roberts, Corran, Cabes, Maite, Collins, Graham P., Devereux, Stephen, Follows, George, Fox, Christopher P., Gribben, John, Hillmen, Peter, Hatton, Chris S., Littlewood, Tim J., McCarthy, Helen, Murray, Jim, Pettitt, Andrew R., Soilleux, Elizabeth, Stamatopoulos, Basile, Love, Sharon B., Wotherspoon, Andrew, Schuh, Anna

“…Richter syndrome (RS) is associated with chemotherapy resistance and a poor historical median overall survival (OS) of 8–10 months. We conducted a phase II…”
Get full text

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline by Schuh, Anna H, Parry-Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E, Fegan, Christopher, Follows, George, Fox, Christopher P, Iyengar, Sunil, Kennedy, Ben, McCarthy, Helen, Parry, Helen M, Patten, Piers, Pettitt, Andrew R, Ringshausen, Ingo, Walewska, Renata, Hillmen, Peter

Get full text

Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia by Mohammad, Ishaque S., Lin, Ke, Oates, Melanie, Khan, Umair T., Burger, Jan, Pettitt, Andrew R., Zhuang, Jianguo

“…The interaction between Chronic lymphocytic leukemia (CLL) cells and monocyte-derived nurse-like cells (NLCs) is fundamentally important to CLL biology…”
Get full text

Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated by Essa, Hani, Pettitt, Andrew R., Lip, Gregory Y. H.

Get full text

Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells by Eagle, Gina L., Herbert, John M. J., Zhuang, Jianguo, Oates, Melanie, Khan, Umair T., Kitteringham, Neil R., Clarke, Kim, Park, B. Kevin, Pettitt, Andrew R., Jenkins, Rosalind E., Falciani, Francesco

“…Chronic lymphocytic leukaemia (CLL) exhibits variable clinical course and response to therapy, but the molecular basis of this variability remains incompletely…”
Get full text

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia by FURMAN, Richard R, SHARMAN, Jeff P, GHIA, Paolo, ERADAT, Herbert, ERVIN, Thomas, LAMANNA, Nicole, COIFFIER, Bertrand, PETTITT, Andrew R, SHUO MA, STILGENBAUER, Stephan, CRAMER, Paula, AIELLO, Maria, COUTRE, Steven E, JOHNSON, Dave M, MILLER, Langdon L, LI, Daniel, JAHN, Thomas M, DANSEY, Roger D, HALLEK, Michael, O'BRIEN, Susan M, CHESON, Bruce D, PAGEL, John M, HILLMEN, Peter, BARRIENTOS, Jacqueline C, ZELENETZ, Andrew D, KIPPS, Thomas J, FLINN, Ian

Get full text